In an era wherein nanotechnology has sparked a huge research interest, brain drug delivery is not an exception. Aiming at fighting several central nervous system (CNS) conditions, tailored nanoparticles open new avenues to address several challenges in the fields of drug delivery and brain targeting. This book gathers contributions from experts in different, complementary fields, having in common their interest in developing new strategies for brain delivery based on nanotechnologies. The book encompasses general aspects pertaining to fundamental development, including tripartite in silico-in vitro-in vivo approaches. It also covers a diversity of nanomedicines applied in treatment and/or diagnosis and monitoring of CNS disorders. Aspects concerning their translation from the bench to clinical practice are also seamlessly discussed. This book will inspire readers to discover possible approaches to holistically delivering drugs into the brain. Edited by Carla Vitorino, Andreia Jorge and Alberto Pais, this book will appeal to anyone involved in nanomedicine, pharmaceutics, neurological and cancer therapies, drug delivery research and computational and regulatory sciences.

New Insights into Glioblastoma: Diagnosis, Therapeutics and Theranostics provides a compendium of recent diagnostic and therapeutic advances in GBM, encompassing a pipeline of compounds and (bio) nanotechnology strategies that have stood out with potential increased antitumoral activity and capability to cross the blood-brain barrier. Issues and challenges related to their translation into the clinical practice and their contribution to the increase in survival rates and well-being of patients are addressed. This is a valuable resource for graduate students, oncologists, cancer researchers and members of the biomedical field who need to learn more on recent developments on the management of glioblastoma. The book is split in three parts: Diagnosis, focusing on biomarkers and techniques such PET/MRI, infrared thermography, and deep neural networks; Therapeutics, discussing new chemical entities, as natural products and repurposed drugs, and new formulation approaches, as nanotechnology-based and microRNA approaches; and Theranostics, explaining the role of omics, system-based approaches, and glioblastoma microenvironment.

This book presents an overview of recent developments for an "old drug", simvastatin. It belongs to the class of statins, the most commonly prescribed drugs for the treatment of dyslipidemia or related diseases, being considered of superior effectiveness for that purpose. Now, millions of patients benefit from the use of simvastatin in preventing coronary heart disease (25 million in 2005 in the United States alone). Additionally, simvastatin has been recently identified as a multifaceted drug, addressing different physiological and pathological conditions, thus extending beyond the conventional cholesterol-dependent mechanisms. It has triggered the development of new strategies in order to promote the respective delivery through novel routes of administration. In this book, a comprehensive selection of topics is presented, encompassing aspects that firstly include chemical synthesis, pharmacology and pharmacoeconomics. In the second part, several delivery systems for new therapeutic areas are explored. These comprise of nanoemulsions administered through the parenteral route, nanostructured lipid carriers for transdermal delivery and supramolecular systems for local applications. Cancer therapy and bone regeneration are some of the therapeutic targets addressed along with the classical treatment of hypercholesterolemia, now in drug combination therapies. This book benefits from the participation of recognised experts from different areas. These include researchers from pharmaceutical technology, pharmacology, synthetic chemistry, and members of regulatory boards.